Statements (36)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
1994
|
| gptkbp:ATCCode |
gptkb:N03AX09
|
| gptkbp:availableOn |
gptkb:brand
generic |
| gptkbp:contraindication |
hypersensitivity to lamotrigine
|
| gptkbp:drugClass |
anticonvulsant
mood stabilizer |
| gptkbp:eliminationHalfLife |
25-33 hours
|
| gptkbp:form |
gptkb:tablet
chewable tablet dispersible tablet |
| gptkbp:genericName |
gptkb:lamotrigine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lamictal
|
| gptkbp:interactsWith |
gptkb:valproic_acid
gptkb:carbamazepine oral contraceptives |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
GlaxoSmithKline
|
| gptkbp:mechanismOfAction |
inhibits voltage-sensitive sodium channels
reduces glutamate release |
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C
|
| gptkbp:prescribes |
adults
children |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:Stevens-Johnson_syndrome
nausea dizziness headache rash insomnia |
| gptkbp:usedFor |
bipolar disorder
epilepsy |
| gptkbp:bfsParent |
gptkb:GSK
|
| gptkbp:bfsLayer |
6
|